Fjarde AP Fonden Fourth Swedish National Pension Fund increased its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 13.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,469 shares of the specialty pharmaceutical company’s stock after buying an additional 2,121 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Jazz Pharmaceuticals PLC were worth $2,716,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the stock. Mn Services Vermogensbeheer B.V. raised its stake in Jazz Pharmaceuticals PLC by 2.8% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 1,601 shares of the specialty pharmaceutical company’s stock worth $217,000 after buying an additional 44 shares during the last quarter. Korea Investment CORP acquired a new position in Jazz Pharmaceuticals PLC during the first quarter valued at $595,000. Profund Advisors LLC increased its position in Jazz Pharmaceuticals PLC by 11.5% in the first quarter. Profund Advisors LLC now owns 2,877 shares of the specialty pharmaceutical company’s stock valued at $418,000 after buying an additional 296 shares during the period. Sumitomo Mitsui Asset Management Company LTD increased its position in Jazz Pharmaceuticals PLC by 16.8% in the first quarter. Sumitomo Mitsui Asset Management Company LTD now owns 4,910 shares of the specialty pharmaceutical company’s stock valued at $712,000 after buying an additional 707 shares during the period. Finally, Wells Fargo & Company MN increased its position in Jazz Pharmaceuticals PLC by 0.5% in the first quarter. Wells Fargo & Company MN now owns 503,759 shares of the specialty pharmaceutical company’s stock valued at $73,111,000 after buying an additional 2,529 shares during the period. 88.24% of the stock is currently owned by institutional investors and hedge funds.

Shares of Jazz Pharmaceuticals PLC (JAZZ) opened at 147.57 on Friday. Jazz Pharmaceuticals PLC has a 52 week low of $95.80 and a 52 week high of $163.75. The firm has a market cap of $8.86 billion, a price-to-earnings ratio of 22.73 and a beta of 1.13. The firm’s 50-day moving average price is $151.04 and its 200-day moving average price is $149.06.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share for the quarter, missing the consensus estimate of $1.85 by $0.13. Jazz Pharmaceuticals PLC had a return on equity of 22.75% and a net margin of 25.69%. The business had revenue of $394.39 million for the quarter, compared to analyst estimates of $410.83 million. During the same period in the prior year, the firm posted $2.67 EPS. Jazz Pharmaceuticals PLC’s revenue for the quarter was up 3.5% on a year-over-year basis. Equities research analysts expect that Jazz Pharmaceuticals PLC will post $10.89 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Fjarde AP Fonden Fourth Swedish National Pension Fund Has $2.72 Million Position in Jazz Pharmaceuticals PLC (JAZZ)” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The legal version of this report can be viewed at https://www.watchlistnews.com/fjarde-ap-fonden-fourth-swedish-national-pension-fund-has-2-72-million-position-in-jazz-pharmaceuticals-plc-jazz/1537656.html.

Several research firms recently weighed in on JAZZ. Janney Montgomery Scott reiterated a “buy” rating and set a $192.00 target price (up from $180.00) on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday, August 9th. Deutsche Bank AG set a $175.00 target price on Jazz Pharmaceuticals PLC and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Cowen and Company reiterated an “outperform” rating and set a $190.00 target price on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday, August 9th. Leerink Swann increased their target price on Jazz Pharmaceuticals PLC from $169.00 to $170.00 and gave the stock a “buy” rating in a research report on Tuesday, July 4th. Finally, Piper Jaffray Companies reiterated a “buy” rating and set a $177.00 target price on shares of Jazz Pharmaceuticals PLC in a research report on Thursday, August 10th. One analyst has rated the stock with a sell rating, three have issued a hold rating and nineteen have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $180.96.

In related news, EVP Michael Patrick Miller sold 200 shares of the business’s stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $150.65, for a total transaction of $30,130.00. Following the completion of the transaction, the executive vice president now owns 22,223 shares of the company’s stock, valued at approximately $3,347,894.95. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Paul Treacy sold 1,304 shares of the business’s stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $143.32, for a total value of $186,889.28. The disclosure for this sale can be found here. Insiders have sold a total of 7,917 shares of company stock valued at $1,223,227 in the last three months. 4.30% of the stock is owned by insiders.

Jazz Pharmaceuticals PLC Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Institutional Ownership by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.